Indeed, in this study, while we observed higher risks of breast cancer mortality for prolactin-elevating antipsychotics than prolactin-sparing in the overall cohort (HRadj, 2.27 95%CI 1.90–2.72; HRadj,1.27 95%CI 0.87–1.87, respectively), this failed to follow a dose-response pattern and associations were attenuated when comparing prolactin-elevating to prolactin-sparing antipsychotics. Here, PRL is linked to breast carcinoma.